Kodiak Sciences Inc. (KOD)
| Previous close | 3.3800 |
| Open | 3.2900 |
| Bid | 3.2100 x 100 |
| Ask | 3.2400 x 200 |
| Day's range | 3.1700 - 3.2900 |
| 52-week range | 1.3700 - 9.8000 |
| Volume | |
| Avg. volume | 881,651 |
| Market cap | 168.9M |
| Beta (5Y monthly) | 2.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter and year ended December 31, 2023.
- PR Newswire
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024. Management will host a conference call and live webcast to discuss recent business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024.
- PR Newswire
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that first time results of the KSI-501ABC Phase 1 Study will be presented at the Angiogenesis, Exudation, and Degeneration 2024 virtual meeting. KSI-501ABC is the second product candidate built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform.
